BOM

Brean Capital has downgraded Pacira Pharmaceuticals Inc (NASDAQ: PCRX) to Hold from Buy after the FDA said it is evaluating adverse event reports of local anesthetic systemic toxicity (LAST) with company's drug Exparel. "We are downgrading Pacirato Hold from Buy for what we believe will amount to...